<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002045</url>
  </required_header>
  <id_info>
    <org_study_id>014E</org_study_id>
    <secondary_id>15</secondary_id>
    <nct_id>NCT00002045</nct_id>
  </id_info>
  <brief_title>A Prospective Double-Blind Study of Retrovir in Early HIV Infection</brief_title>
  <official_title>A Prospective Double-Blind Study of Retrovir in Early HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult
      patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in
      the treatment of HIV disease in these patients.

      (12/01/89) Information supplied by drug company update. Study discontinued due to positive
      data from ACTG 016.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Treatment:

        Allowed:

          -  Electron beam therapy to an area of less than 100 cm2.

        Patient must have signs and symptoms of HIV infection confined to those of stages WRII-V or
        CDC groups III IV-A, IV-C-2 (except recurrent Salmonella bacteremia, nocardiosis, or
        disseminated/extrapulmonary Mycobacterium tuberculosis), and IV-E (except diffuse
        interstitial lymphoid pneumonitis).

          -  Patient must be able to give informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Evidence of nervous system dysfunction caused by factors other than HIV infection,
             including chronic alcohol or drug abuse.

          -  Present or prior known AIDS-defining opportunistic infections, lymphomas, or
             malignancies based on CDC criteria.

          -  Present or prior known systemic opportunistic diseases most recently included in the
             expanded CDC definition of AIDS:

          -  extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent
             nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid
             pneumonitis.

          -  Evidence of compromised bone marrow function defined by specified lab values.

          -  Evidence of HIV neurologic disease.

          -  Evidence of HIV-associated &quot;wasting syndrome&quot;.

          -  Hypersensitivity to zidovudine (AZT).

        Concurrent Medication:

        Excluded:

          -  Cytotoxic chemotherapeutic agents.

          -  Steroids.

          -  Interferon or immunomodulating agents.

          -  Any antiretroviral drug including, but not limited to zidovudine (AZT), ribavirin,
             HPA23, AL 721, or phosphonoformate.

        Patients with the following are excluded:

          -  Evidence of nervous system dysfunction caused by factors other than HIV infection,
             including chronic alcohol or drug abuse. Present or prior known AIDS-defining
             opportunistic infections, lymphomas, or malignancies based on CDC criteria. Present or
             prior known systemic opportunistic diseases most recently included in the expanded CDC
             definition of AIDS:

          -  extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent
             nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid
             pneumonitis.

          -  Evidence of compromised bone marrow function defined by specified lab values. Evidence
             of HIV neurologic disease.

          -  Evidence of HIV-associated wasting syndrome.

          -  Hypersensitivity to retrovir.

        Prior Medication:

        Excluded within 4 weeks of study entry:

          -  Interferon.

          -  Immunomodulating agents.

          -  Myelosuppressive drugs.

          -  Nephrotoxic agents.

          -  Other experimental chemotherapy.

        Prior Treatment:

        Excluded:

          -  Treatment with radiation therapy (with the exception of electron beam therapy to an
             area of less than 100 cm2).

        Chronic alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1989</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Prospective Studies</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

